Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06191471Completed

Hepatitis A Virus Induced Acute Acalculous Cholecystitis Diagnosed Postoperatively: Case Report

Role: lead

NCT06050876Completed

Gallbladder Volvulus Diagnosed Intraoperatively: Case Report

Role: lead

NCT05204420Completed

Spontaneous Gastric Intramural Hematoma: Case Report and Literature Review

Role: lead

NCT03758079Phase 4Completed

Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus

Role: lead

All 4 trials loaded